SUNNYVALE, California,
December 20, 2016 /PRNewswire/ --
Practice-Changing Study Presented
at the 2016 Best of ASTRO Meeting
Accuray Incorporated (NASDAQ: ARAY) announced today new data
showing that 80 percent of patients with solitary plasmacytoma of
the bone (SPB) had excellent cancer control four years after
receiving intensity-modulated radiation therapy (IMRT) delivered
with the TomoTherapy® System, in addition to immunomodulatory drugs
(IMiDs) or proteasome inhibitors
(PI).[1] The concurrent treatments
were well-tolerated and toxicity was manageable with standard
approaches.[1] The study was
presented on November 11, 2016 at the
2016 Best of ASTRO meeting, a two-day summary of the ASTRO Annual
Meeting, at which the most relevant and practice-changing abstracts
are presented.
(Logo:
http://photos.prnewswire.com/prnh/20151126/291246LOGO )
(Photo:
http://mma.prnewswire.com/media/450832/Accuray.jpg )
"For patients newly diagnosed with SPB, this study could change
the game. We now have hope that the patients with SBP can live
without disease and without major side effects after treatment with
new targeted agents in addition to precise radiation treatments,"
said Youlia M. Kirova, MD, senior
radiation oncologist at the Curie Institute in Paris and investigator of the study.
"Tolerance was excellent because of the TomoTherapy System's highly
conformal dose distribution which enabled clinicians to deliver
optimal doses of radiation while sparing healthy tissue and also
because of the less toxic new targeted treatments."
"This is a new approach enabling radiation oncologists, medical
oncologists, and hematologists to give their patients prolonged
progression-free survival (PFS)," Fabienne Hirigoyenberry-Lanson,
PhD, vice president medical affairs, at Accuray. "These study
results add to the evidence supporting the TomoTherapy System as an
innovative and safe radiation therapy treatment for hemopathies
such as hematological
cancers.[1],[2]"
SPB is a rare disease with a high rate of progression to
multiple myeloma (MM). The role of systemic treatments given
concurrently with radiation therapy was uncertain in SPB and had
never been evaluated
This study is the first to investigate whether patients who
received a short course of IMiD or PI in addition to IMRT delivered
with the TomoTherapy System had a longer progression free survival
than patients treated only with IMRT. The study showed that:
- All patients (100 percent) in the study achieved local control
of the plasmacytoma and no local relapse was observed;
- Overall survival was more than 95 percent at four years;
- PFS rates at 48 months were significantly prolonged in patients
receiving the association (80.0 percent versus 50.3
percent).;
- Toxicity was mostly hematological, occurring in the patients
receiving the combined therapy, and was manageable with standard
approaches.
About the Study
The study titled "Intensity Modulated Radiation Therapy by
Tomotherapy (IMRT) Concurrent With a Short Systemic Treatment for
Solitary Plasmacytoma of the Bone (SPB) With Improvement of
Progression-Free Survival" (1) is a retrospective analysis of the
medical and dosimetry records of 28 consecutive patients treated
for SPB in the Department of Radiation Oncology at the Curie
Institute between 2004 and 2013. All patients had histologically
proven plasmacytoma of the bone, without bone marrow involvement.
Fifteen patients received the standard treatment, 40 Gy
radiotherapy, and 13 patients received treatment with IMiDs or PIs,
in addition to the 40 Gy radiotherapy delivered by IMRT.
Important Safety Information
For Important Safety Information please refer to
http://www.accuray.com/safety-statement-radiationtreatment
About the TomoTherapy® System
The Accuray TomoTherapy H™ Series efficiently enables physicians
to customize treatment plans for the entire range of radiation
therapy patients and disease types. Its innovative design enables
treatment plans to be delivered with integrated, daily CT image
guidance, enhancing accuracy and delivering highly precise,
intensity-modulated radiation for more optimal sparing of healthy
tissue and critical structures.
About Accuray
Accuray Incorporated (NASDAQ: ARAY) is a radiation oncology
company that develops, manufactures, and sells precise, innovative
tumor treatment solutions that set the standard of care with the
aim of helping patients live longer, better lives. The company's
leading-edge technologies deliver the full range of radiation
therapy and radiosurgery treatments. For more information, please
visit http://www.accuray.com .
Safe Harbor Statement
Statements made in this press release that are not statements of
historical fact are forward-looking statements and are subject to
the "safe harbor" provisions of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements in this press
release relate, but are not limited, to clinical applications,
clinical results, patient outcomes and Accuray's leadership
position in radiation oncology innovation and technologies.
Forward-looking statements are subject to risks and uncertainties
that could cause actual results to differ materially from
expectations, including but not limited to the risks detailed from
time to time under the heading "Risk Factors" in the company's
report on Form 10-K, filed on August 24,
2016, the company's report on Form 10-Q, filed on
November 1, 2016, and as updated
periodically with the company's other filings with the SEC.
Forward-looking statements speak only as of the date the
statements are made and are based on information available to
Accuray at the time those statements are made and/or management's
good faith belief as of that time with respect to future events.
The company assumes no obligation to update forward-looking
statements to reflect actual performance or results, changes in
assumptions or changes in other factors affecting forward-looking
information, except to the extent required by applicable securities
laws. Accordingly, investors should not put undue reliance on any
forward-looking statements.
References
- Le Ray E, et al. Intensity Modulated Radiation Therapy
by Tomotherapy (IMRT) Concurrent With a Short Systemic Treatment
for Solitary Plasmacytoma of the Bone (SPB) With Improvement of
Progression-Free Survival. Int J Radiat Oncol Biol Phys 2016;
96(2S):S22.
http://www.redjournal.org/article/S0360-3016(16)30392-3/abstract
- Chargari C, et al. The role of helical tomotherapy in
the treatment of bone plasmacytoma. Med Dosim 2012 Spring;
37(1):26-30.
Press Contacts:
Sancie Nakarat, Accuray
Tel : +33-6-81-36-84-34
E-Mail : snakarat@accuray.com
Liliana Silva Fernandes, Elan
Edelman
Tel : +33-1-86-21-50-37
E-Mail : liliana.silvafernandes@elanedelman.com